New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
17:11 EDTEXASExact Sciences' Cologuard shows 'unprecedented' rates of cancer detection
According to the Mayo Clinic, results of a clinical trial of Cologuard show unprecedented rates of precancer and cancer detection by a noninvasive test. The detection rates are similar to those reported for colonoscopy. The results were published in the March 20 issue of the New England Journal of Medicine. Cologuard was co-developed by Mayo Clinic and Exact Sciences. Cologuard, is a noninvasive sDNA test for the early detection of colorectal precancer and cancer. The clinical trial, called the DeeP-C study, included 10,000 patients and was designed to determine how well Cologuard detects precancer and cancer. The study also compared Cologuard to the fecal immunochemical test for occult blood. The study was conducted at 90 medical centers throughout the United States and Canada. According to the Mayo Clinic's website, the release is under embargo until March 19, at 5:00 pm ET, though it was visible on the "News Resources" section of the site. As of 5:00 pm ET on March 18, the post appeared to have been removed. Shares of Exact, which gained $1.29, or 9.82%, to close at $14.42 during today's session, are up an additional $1.09, or 7.56%, to $15.51 in after hours trade. Reference Link
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
15:49 EDTEXASExact Sciences says CMS advisors vote to maintain Cologuard reimbursement rate
Subscribe for More Information
August 24, 2015
08:00 EDTEXASExact Sciences price target lowered to $26 from $32 at Canaccord
Canaccord lowered its price target on Exact Sciences to $26 from $32 to reflect dilution of the large secondary offering. The firm maintains its Buy rating on Exact Sciences shares, citing its sales force expansion, payer traction and a high probability of a positive outcome from the USPSTF decision.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use